TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05855837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready to Eat Cereal
Description: Cereal products available in retail stores

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready to Eat Cereal
Description: Cereal products available in retail stores
Study: NCT06195618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide pulsed autologous Dendritic cell
Description: Intradermal vaccination with peptide-pulsed autologous dendritic cells in 200 µL of patient's serum in six doses weekly after surgery.
Study: NCT05499884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovaginal ultrasound
Description: Endovaginal ultrasound will be performed in the operating room by the radiology team to:~1. to confirm the operative indication for a rectal shaving ;~2. to confirm the complete removal of the lesion
Study: NCT04659707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Xe129
Description: Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.
Study: NCT04527029

Intervention type: OTHER
Intervention: No interventions
Description: It is an observational study. No interventions.
Study: NCT05724342

Intervention type: DRUG
Intervention: rhTNK-tPA Thrombolysis
Description: rhTNK-tPA Thrombolysis
Study: NCT04997876

Intervention type: OTHER
Intervention: Biomarker analysis
Description: Biomarkers from presurgical OCTs are assessed
Study: NCT04424225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 25 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 25 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: 100 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: 100 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
Study: NCT05944185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: αPD1-MSLN-CAR T Cells
Description: αPD1-MSLN-CAR T Cells
Study: NCT04687852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative and Non-conservative treatments
Description: This program includes Focused Pelvic Floor with Motor Imagery Technique Group ,Nonsteroidal Anti-Inflammatory Drug Group, Diosmin Group, Acupressure Group (LI-4 (Bilateral), CV-6, CV-4, SP-6 (Bilateral). It is aimed to determine the most effective treatment among these groups.

Intervention type: OTHER
Group type: OTHER
Intervention: Conservative and Non-conservative treatments
Description: This program includes Focused Pelvic Floor with Motor Imagery Technique Group ,Nonsteroidal Anti-Inflammatory Drug Group, Diosmin Group, Acupressure Group (LI-4 (Bilateral), CV-6, CV-4, SP-6 (Bilateral). It is aimed to determine the most effective treatment among these groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative and Non-conservative treatments
Description: This program includes Focused Pelvic Floor with Motor Imagery Technique Group ,Nonsteroidal Anti-Inflammatory Drug Group, Diosmin Group, Acupressure Group (LI-4 (Bilateral), CV-6, CV-4, SP-6 (Bilateral). It is aimed to determine the most effective treatment among these groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative and Non-conservative treatments
Description: This program includes Focused Pelvic Floor with Motor Imagery Technique Group ,Nonsteroidal Anti-Inflammatory Drug Group, Diosmin Group, Acupressure Group (LI-4 (Bilateral), CV-6, CV-4, SP-6 (Bilateral). It is aimed to determine the most effective treatment among these groups.
Study: NCT04865588

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rotational atherectomy
Description: angioplasty with rotational atherectomy - a rotating instrument used to break up the calcification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rotational atherectomy
Description: angioplasty with rotational atherectomy - a rotating instrument used to break up the calcification

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cutting balloon
Description: a balloon with microsurgical blades on its outer surface which make longitudinal incisions in the calcified area in order to open resistant clogs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plain old balloon
Description: current standard treatment of stent placement
Study: NCT05277168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1904
Description: Single Arm ：It is a dose-escalation and dose-expansion study of SHR-A1904 in subjects with advanced solid tumors
Study: NCT05286853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Participants receiving institutional standard of care will have a kidney biopsy followed by 2 REACT injections into biopsied and non-biopsied contralateral kidneys 3 months (+30 days) apart and will be followed for 5 years (60 months) since last REACT injection.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Participants receiving institutional standard of care will have 2 sham procedures that simulate real biopsy and injection procedure. No tissue is taken during biopsy and nothing is injected into kidney. The second sham procedure will occur 3 months (+30 days) after the first sham procedure. Participants will be followed for 5 years (60 months) since last sham REACT injection.
Study: NCT05388981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBT115301
Description: Immunomodulatory dimeric fusion protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBT115301
Description: Immunomodulatory dimeric fusion protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBT115301
Description: Immunomodulatory dimeric fusion protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBT115301
Description: Immunomodulatory dimeric fusion protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBT115301
Description: Immunomodulatory dimeric fusion protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study: NCT05396534

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial Fibrillation transcatheter ablation
Description: We perform pulmonary veins isolation that remains remains the cornerstone of all catheter-based treatment strategies in atrial fibrillation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation transcatheter ablation
Description: We perform pulmonary veins isolation that remains remains the cornerstone of all catheter-based treatment strategies in atrial fibrillation
Study: NCT05388981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study: NCT05419011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo SOC colonoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy
Description: Undergo SOC colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo SOC colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo SOC colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nogapendekin Alfa
Description: Given nogapendekin alfa inbakicept (N-803) SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nogapendekin Alfa
Description: Given nogapendekin alfa inbakicept (N-803) SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04993105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + Graston.
Description: In graston + exercises treatment will be same but after exercises added with proper application of graston which included application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin.The Graston tools will be then used to mobilize the tissues of the triceps surae and plantar foot. In areas of increased tissue restriction, more aggressive pressure with graston was applied using increased force and shorter strokes over the areas of restrictionIce was offered as needed for pain management after each session. This will be continued for three sessions. NPRS score, score on FADI and dorsiflexors range will be assessed after treatment of two weeks. Along with conventional treatment.~.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise only
Description: gastrocnemius and plantarstretching
Study: NCT06316895

Intervention type: PROCEDURE
Intervention: thyroid surgery
Description: thyroid lobectomy

Intervention type: PROCEDURE
Intervention: ultrasound-guided thermal ablation
Description: radiofrequency ablation; microwave ablation or laser ablation
Study: NCT04633681

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sweetener and sweetness enhancer consumption
Description: Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sweetener and sweetness enhancer consumption
Description: Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sweetener and sweetness enhancer consumption
Description: Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sweetener and sweetness enhancer consumption
Description: Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sweetener and sweetness enhancer consumption
Description: Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sweetener and sweetness enhancer consumption
Description: Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sweetener and sweetness enhancer consumption
Description: Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
Study: NCT05965596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a psycho educational intervention program
Description: The program was developed by the researcher herself based on recommendations derived from a systematic review of psychoeducational interventions to improve the quality of Life and psychological outcomes in gynecological cancer patients. Also guided by the program adopted by chow et all in 2014(28) to test the feasibility of implementing a psychoeducational intervention program for gynecological cancer patients.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: the routine care
Description: the routine care provided for all gynecological cancer patients in the study setting
Study: NCT05908396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-2644
Description: IGM-2644 is an engineered, bispecific IgM antibody directed against CD3 and CD38. IGM-2644 is designed to bind to CD38 to selectively target and kill myeloma cancer cells through both T-cell dependent cellular toxicity (TDCC) and complement dependent cytotoxicity (CDC) activities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-2644
Description: IGM-2644 is an engineered, bispecific IgM antibody directed against CD3 and CD38. IGM-2644 is designed to bind to CD38 to selectively target and kill myeloma cancer cells through both T-cell dependent cellular toxicity (TDCC) and complement dependent cytotoxicity (CDC) activities.
Study: NCT05689203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS1128
Description: dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS1128
Description: dose 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04981795

Intervention type: DRUG
Intervention: Tafasitamab
Description: Observational Study on safety and effectiveness of tafasitamab in combination with lenalidomide inPatients With Relapsed or Refractory DLBCL.

Intervention type: DRUG
Intervention: Tafasitamab
Description: Observational Study on safety and effectiveness of tafasitamab in combination with lenalidomide inPatients With Relapsed or Refractory DLBCL.
Study: NCT06393439

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Virtual reality motor task
Description: After a short practice task, participants perform motor tasks in a virtual reality environment. Reaction time is used to assess task performance.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Virtual reality motor task
Description: After a short practice task, participants perform motor tasks in a virtual reality environment. Reaction time is used to assess task performance.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Virtual reality motor task
Description: After a short practice task, participants perform motor tasks in a virtual reality environment. Reaction time is used to assess task performance.
Study: NCT06273449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 3 - 3D Printed Removable Partial Denture
Description: Teeth Profile Capture Method: Intraoral scan RPD Design Method: Based on intraoral scan, using design software RPD Fabrication Method: Additive manufacturing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 2 - 3D Printed Removable Partial Denture
Description: Teeth Profile Capture Method: Physical impression RPD Design Method: Based on stone model, using design software RPD Fabrication Method: Additive manufacturing
Study: NCT05162274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib(G001)
Description: Current formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib(G001)
Description: Current formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib(G002)
Description: New formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib(G002)
Description: New formulation
Study: NCT05451004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymphatic Mapping with SPECT-CT
Description: Radiation: Ipsilateral Neck Radiotherapy and SPECT-CT Guided Contralateral Neck Radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ipsilateral and Contralateral Neck
Description: Radiotherapy
Study: NCT04635969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Health and Development Education for Children With Intellectual Disability
Description: Sexual Health and Development Education for Children With Intellectual Disability: It is aimed to eliminate the problems related to personal care and cleaning of children with mental retardation, to learn the symptoms of adolescence and to learn the methods of protection from abuse.
Study: NCT06148363

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Definition transcranial Direct Current Stimulation (HD-tDCS)
Description: tDCS, or Transcranial Direct Current Stimulation, is a non-invasive brain stimulation technique that involves applying a small, constant direct current through electrodes placed on the scalp to modulate neuronal activity in specific brain regions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham High-Definition transcranial Direct Current Stimulation (HD-tDCS)
Description: In the sham condition, tDCS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 20-minute intervention.
Study: NCT06125145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Geriatric Assessment and Promotora Coaching
Description: In Visit 1 the community health worker/promotora will assess frailty, cognition, polypharmacy, depression, symptom burden, and social support. In Visits 2 and 3 the community health worker will deliver interpersonal communication techniques to deliver the problem solving coaching format, leverage cultural congruence with clients, and provide social support to assist in adopting healthy behaviors.
Study: NCT05181787

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics
Description: Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics
Description: Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics
Description: Metabolomic data were obtained by UPLC-QTOF/MS platform.

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics
Description: Metabolomic data were obtained by UPLC-QTOF/MS platform.
Study: NCT04157725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mild stimulation protocol: oral Clomiphene Citrate
Description: Group A (mild stimulation protocol) will receive oral Clomiphene Citrate (Clomid®) 150 mg/day for 5 days (starting on the 2nd of menses), followed by FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting from the 6th day of the menstrual cycle. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Stimulation Protocol: will receive FSH/HMG
Description: Group B (conventional stimulation protocol) will receive FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting on the 2nd day of menses. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
Study: NCT06274398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF/EVG rectal insert
Description: Phase 1: rectal inserts applied daily for 3 consecutive days Phase 2: rectal inserts applied every other day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo rectal insert
Description: Phase 1: rectal inserts applied daily for 3 consecutive days Phase 2: rectal inserts applied every other day for 14 days
Study: NCT05217667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-ANG 3 Injection
Description: Participants will be randomized to receive ARO-ANG3 SC on Day 1 and Day 84 during the initial 36 Weeks of the study and on Day1 and Months 3, 6, 9, 12, 15, 18, and 21 of the extension period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-ANG 3 Injection
Description: Participants will be randomized to receive ARO-ANG3 SC on Day 1 and Day 84 during the initial 36 Weeks of the study and on Day1 and Months 3, 6, 9, 12, 15, 18, and 21 of the extension period